ArticleMedicine2026
Rare glandular tumors of the nasopharynx: A retrospective cohort study of papillary adenocarcinoma and salivary gland-type carcinomas.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal papillary adenocarcinomas (NPAC) and salivary gland-type nasopharyngeal carcinomas (SGNPCs) are rare tumors, accounting for approximately 0.38 to 0.48% of all nasopharyngeal malignancies. These tumors exhibit distinct clinical and pathological features and require different management approaches compared with conventional nasopharyngeal carcinoma. Given the limited literature, we conducted a retrospective study of 20 patients diagnosed with NPAC or SGNPC at our institution to summarize their clinical characteristics, treatment modalities, and outcomes. This retrospective study included 20 patients with pathologically confirmed NPAC or SGNPC treated at the Vietnam National Cancer Hospital from January 2019 to January 2026. A total of 20 patients were included, comprising 12 patients with NPAC and 8 patients with SGNPC. Tumors were mainly located at the roof or posterior margin of the nasopharynx, and most patients presented with early-stage disease (T1-T2) without cervical lymph node metastasis. All patients underwent endoscopic endonasal surgery, 6 patients were treated with surgery alone, while the remaining patients received postoperative radiotherapy using intensity-modulated radiation therapy. Postoperative complications were generally mild, including minor bleeding in one patient (5%) and dermatitis in all patients who received radiotherapy (100%). The median follow-up was 49.7 months (range, 4.5-84.0 months). The estimated 3-year and 5-year overall survival and disease-free survival rates were both 100% (95% confidence interval, 83.2-100%). Primary nasopharyngeal adenocarcinoma and salivary gland-type carcinoma are rare entities. In this cohort, the majority of patients presented at an early stage, and surgical intervention was the mainstay of treatment with favorable outcomes. However, these findings should be interpreted with caution given the small sample size and the surgically selected, early-stage nature of this cohort, and should be considered hypothesis-generating rather than definitive. Further prospective studies with larger patient populations and longer follow-up are needed to better define optimal treatment strategies and long-term outcomes for these rare tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.